Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INCB053914 · 1 trial · 2 indications
TEAE is defined as an adverse event reported for the first time or worsening of a pre-existing event after the first dose of study treatment.
| Arm | Type | Description |
|---|---|---|
| INCB053914 + INCB050465 | EXPERIMENTAL | INCB053914 in combination with INCB050465. |
| Name | Type | Description |
|---|---|---|
| INCB053914 | DRUG | Dose Escalation: INCB053914 at the protocol-defined starting dose in combination with INCB050465, with dose modifications based on tolerability criteria. Dose Expansion: Recommended dose from the dose-escalation study. |
| INCB050465 | DRUG | Dose Escalation: INCB050465 at the protocol-defined starting dose in combination with INCB053914, with dose modifications based on tolerability criteria. Dose Expansion: Recommended dose from the dose-escalation study. |
Inclusion Criteria: * Relapsed or refractory DLBCL, which has been histologically documented, defined as having received at least 2 but no more than 5 prior systemic treatment regimens (eg, an anti-CD20 antibody, an anti-CD20 antibody with or without chemotherapy, or chemotherapy alone) and ineligi...
INCB053914 is an investigational small molecule being studied for the treatment of relapsed diffuse large B-cell lymphoma (DLBCL). It is being evaluated in combination with another agent in patients with relapsed or refractory DLBCL. The drug is not approved and remains in clinical development.
INCB053914 is being developed by Incyte Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol INCY. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational drug in patients with relapsed or refractory diffuse large B-cell lymphoma.
INCB053914 is in Phase 1 clinical development. A Phase 1 study has been completed, evaluating the drug in combination with INCB050465 in patients with relapsed or refractory diffuse large B-cell lymphoma. The drug is investigational and has not been approved by regulatory authorities.
INCB053914 has been studied in one clinical trial, identified as NCT03688152. This was a Phase 1, open-label, uncontrolled study conducted in the United States, evaluating the safety and tolerability of INCB053914 in combination with INCB050465 in patients with relapsed or refractory diffuse large B-cell lymphoma. The trial enrolled 9 participants and has been completed.
No, INCB053914 is not the same as INCB050465. INCB053914 is the investigational drug being studied, while INCB050465 is a separate agent used in combination with INCB053914 in the clinical trial. The study evaluated the safety and tolerability of the combination in patients with relapsed or refractory diffuse large B-cell lymphoma.